Affordable Access

Publisher Website

Modulation of Prostate Carcinoma Cell Growth and Apoptosis by Chromogranin A

The Journal of Urology
Publication Date
DOI: 10.1097/01.ju.0000091807.02246.f3
  • Prostate
  • Prostatic Neoplasms
  • Apoptosis Chromogranin A
  • Caspases
  • Chemistry


ABSTRACT Purpose We elucidated the effect and possible pathways of chromogranin A in regulating prostatic cancer cell growth. Materials and Methods Chromogranin A expression in prostatic cancer cell lines were detected with immunofluorescence flow cytometry (FCM) and the inhibition of cell growth due to chromogranin A antibody was measured using microculture tetrazolium. Cell cycle and RNA changes were evaluated with acridine orange FCM. Intracellular chromogranin A variations were detected with FCM, as were apoptotic changes, p53, Fas and tumor necrosis factor-α. Apoptosis and caspase-3 expression of tumor cells was assessed with dual immunohistochemical staining. Results Increased chromogranin A expression was observed in PC-3, DU145 and LNCap cells independent of hormone dependence. Dose and time dependent growth inhibition occurred at 12 hours. Chromogranin A antibody arrested PC3 cells in the S-phase immediately after treatment. The number of G0/G1 and G2/M cells subsequently decreased. PC3 tumor cells had transiently increased RNA at 12 hours with a marked decrease at 48 hours. Decreasing chromogranin A expression started at 12 hours and was most prominent at 48 hours. Apoptotic cells markedly increased at 12 hours with an increase in p53, Fas and tumor necrosis factor-α (Fas more than the others). Increased apoptotic cell and caspase-3 expression was observed on immunohistochemical stains. Conclusions Chromogranin A is an important neuropeptide regulating the growth of prostate cancer cells. Specific antibodies can suppress its function through apoptotic pathways (Fas and caspase-3), leading to programmed cell death. Chromogranin A antibody mediated apoptosis may be a specific alternative treatment for prostate cancer.

There are no comments yet on this publication. Be the first to share your thoughts.